Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181 ↗

Phase 2 Completed 632 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.

Timeline

Start: 2013-12-02
Primary completion: 2014-12-11
Completion: 2014-12-11

Publications

Results Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 Oct 17;318(15):1460-1470. doi: 10.1001/jama.2017.14752.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Semaglutide	Peptide	1 mg	Oral
Comparator	Semaglutide	Peptide	2.5 mg	Oral
Comparator	Semaglutide	Peptide	5 mg	Oral
Comparator	Semaglutide	Peptide	10 mg	Oral
Comparator	Semaglutide	Peptide	20 mg	Oral
Comparator	Semaglutide	Peptide	40 mg	Oral

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications